TEE
NKTR icon

Tibra Equities Europe’s Nektar Therapeutics NKTR Stock Holding History

Tibra Equities Europe’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-713
Closed -$381K – 293
2019
Q2 		$381K Buy
+713
New +$358K 0.03% 203
2018
Q3 		– Sell
-11,546
Closed -$8.46M – 234
2018
Q2 		$8.46M Buy
+11,546
New +$13.3M 1.27% 20

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tibra Equities Europe's NKTR Position: Q3 2019 in Review

Tibra Equities Europe sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 713 shares — an estimated $381K sold.

Tibra Equities Europe first reported a position in NKTR in Q2 2018 and held it in 2 quarters. The position peaked at $8.46M in Q2 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Tibra Equities Europe reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 713 Nektar Therapeutics shares in Q3 2019, an estimated $381K.
  • Tibra Equities Europe first reported a position in Nektar Therapeutics in Q2 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Nektar Therapeutics position peaked at $8.46M in Q2 2018.
  • 287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.